Evidence map›Paper›PMID 38690895›Full record

ArticleAntimicrobial agents and chemotherapy2024

Insights into the activity of cefiderocol against PER-2 producing Enterobacterales.

Melina Ruggiero, Ivan Briceño Muñoz, Gabriel Gutkind, Andrea M Hujer, Robert A Bonomo, Pablo Power

Abstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Melina RuggieroUniversidad de Buenos Aires, Instituto de Investigaciones en Bacteriología y Virología Molecular (IBaViM), Buenos Aires, Argentina.
Ivan Briceño MuñozUniversidad de Buenos Aires, Instituto de Investigaciones en Bacteriología y Virología Molecular (IBaViM), Buenos Aires, Argentina.
Gabriel GutkindUniversidad de Buenos Aires, Instituto de Investigaciones en Bacteriología y Virología Molecular (IBaViM), Buenos Aires, Argentina.ORCID 0000-0003-1999-9785
Andrea M HujerResearch Service, Louis Stokes Cleveland Department of Veterans Affairs, Cleveland, Ohio, USA.
Robert A BonomoResearch Service, Louis Stokes Cleveland Department of Veterans Affairs, Cleveland, Ohio, USA.ORCID 0000-0002-3299-894X
Pablo PowerUniversidad de Buenos Aires, Instituto de Investigaciones en Bacteriología y Virología Molecular (IBaViM), Buenos Aires, Argentina.ORCID 0000-0002-7051-9954

Funding

Characterizing novel Beta-lactamases from metagenomic samples: insights into the evolution of antimicrobial resistance from the environment towards human-associated pathogensR01AI160371 · NIAID · UBATEC S.A. · PI Pablo Power · 2022 to 2026
$630k
Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) PIP 11220200100191COMINCyT | Agencia Nacional de Promoción Científica y Tecnológica (ANPCyT) PICT 2021-00771NIAID NIH HHS R01 AI160371Shionogi (Shionogi & Co. Ltd.) 2021-IIR-000033
6 · The paper itself

Abstract

The PER-2 β-lactamase is a unique class A enzyme conferring broad spectrum cephalosporin resistance. In this study, we explored the stability of cefiderocol (FDC) against PER-2 β-lactamase to gain insights into structure activity relationships (SAR) of this synthetic siderophore-conjugated antibiotic. Herein, we show that the MICs of FDC for PER-2 producing isolates and transformants ranged between 0.125 and 64 µg/mL; diazabicyclooctanes (DBOs) reduced the MIC values. In PER-2 mutants, MIC values decreased up to 10-12 dilutions in agreement with previous observations especially in the case of Arg220 substitutions. Catalytic efficiency for PER-2 was 0.072 µM

Indexed as

Anti-Bacterial Agentsbeta-LactamasesCefiderocolCephalosporinsMicrobial Sensitivity TestsCatalytic DomainEnterobacteriaceaeStructure-Activity RelationshipAnti-Bacterial Agentsbeta-LactamasesCefiderocolCephalosporinsArg220diazabicyclooctanesdockingenzyme kineticsESBLsiderophore-conjugated

Identifiers

PMID38690895
PMCPMC11620487

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.